The industry’s focus is on living organisms, and the strict controlled standards make it a unique concern for business leaders. These attributes make the industry an ideal source of technological innovation, resulting in significant breakthroughs that have increased the quality of agriculture, led to the creation of biofuels, and even led to life-saving pharmaceutical products.

Biotech companies that are starting out have many options when it comes down to revenue generation strategies, with the majority opting for either a technology partnering or an approach to asset creation and out-licensing. Technology partnering generates faster revenues with less financial risk while out-licensing and asset creation strategy generates significantly higher returns when it’s successful. A growing number of biotechs that are in research phase operate a hybrid model which combines both strategies.

If you choose to go with an approach that is focused on product development can achieve commercial success if they can get their pipeline to a suitable stage and also attract a significant pharmaceutical partner or investor with a large sum of money. This is a costly investment. It is crucial to balance the opportunistic approach of leveraging assets from outside and make best scientific decisions for the development of home-grown products.

In addition, the «platform» model can provide an alternative path to www.genotec-frankfurt.de/biotechnological-synthesis-of-remedies/ revenue. It is less costly than product-oriented development but also involves significant risk. In this model, a biotech is the owner and develops its platform technology, before collaboration with big pharma firms to generate a portfolio of drug discovery projects that target specific diseases (i.e. disease the x gene within biology y). Advinus Therapeutics, among others have adopted this strategy.